His tirzepatide is ready ... to further sieve out impurities when mixing his ingredients, a process called reconstitution, which he learned from an instructional video and written guide widely ...

MÁLAGA, Spain — In the first head-to-head trial of its kind, tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity; Eli Lilly) produced significantly greater weight loss ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

Adults receiving tirzepatide lost more weight and had a greater decline in waist circumference than those receiving semaglutide. The proportion of adults experiencing adverse events was similar in ...

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

The SURMOUNT-5 trial, published over the weekend in the New England Journal of Medicine and presented at the European Congress on Obesity, showed that treatment with tirzepatide (Zepbound; Eli Lilly) ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published, examining their ability to reduce weight and waist circumference.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

New animal research being presented at the European Congress on Obesity (ECO25) in Malaga, Spain (11–14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment ...

Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose weight and keep it off. But until now, no one had directly compared their performance in people without ...